Literature DB >> 16006463

A prospective, longitudinal study of the renin-angiotensin system, prostacyclin and thromboxane in the first trimester of normal human pregnancy: association with birthweight.

H Al Kadi1, H Nasrat, F Broughton Pipkin.   

Abstract

BACKGROUND: Very early human pregnancy is a state of cardiovascular underfilling. The renin-angiotensin system (RAS) is directly concerned with sodium and water homeostasis. Angiotensinogen is known to be the rate-limiting component in the generation of angiotensin I, and hence angiotensin II, in pregnancy. The usual measurement of 'renin activity' does not differentiate between enzyme and substrate. We hypothesized that the RAS is activated from the start of pregnancy; plasma renin concentration (PRC) and angiotensinogen will show differential regulation and might stimulate the rise in prostacyclin.
METHODS: A prospective study of 12 nulliparous normal women. PRC and angiotensinogen and excretion of prostacyclin and thromboxane metabolites were measured pre-pregnancy and four to six times after conception to 13 weeks.
RESULTS: By 6 weeks gestation, mean PRC was markedly raised and remained stable to 13 weeks. The initial angiotensinogen response varied, but rose consistently after 6-8 weeks. Regression analysis showed angiotensinogen in the first trimester to be strongly associated with corrected birthweight centile (P < 0.001). Excretion of eicosanoid metabolites was very variable, but rose significantly from 6 weeks; the ratio between prostacyclin and thromboxane excretion did not alter over this time. There was no correlation between the various hormones measured.
CONCLUSION: Angiotensinogen is known to be rate-limiting in pregnancy. Its association with birthweight may be through effects on early plasma volume expansion and may have implications for intrauterine growth restriction and pre-eclampsia.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16006463     DOI: 10.1093/humrep/dei184

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  7 in total

1.  Coagulation and prothrombotic state parameters: a clinical analysis during early pregnancy.

Authors:  H Chen; L Zhou; L Meng; M Liu; J Tan; L Gao; J Zhang
Journal:  Ir J Med Sci       Date:  2011-08-02       Impact factor: 1.568

2.  The impact of maternal protein restriction during rat pregnancy upon renal expression of angiotensin receptors and vasopressin-related aquaporins.

Authors:  Ruth Cornock; Simon C Langley-Evans; Ali Mobasheri; Sarah McMullen
Journal:  Reprod Biol Endocrinol       Date:  2010-08-31       Impact factor: 5.211

Review 3.  Diabetic Nephropathy in Women With Preexisting Diabetes: From Pregnancy Planning to Breastfeeding.

Authors:  Lene Ringholm; Julie Agner Damm; Marianne Vestgaard; Peter Damm; Elisabeth R Mathiesen
Journal:  Curr Diab Rep       Date:  2016-02       Impact factor: 4.810

4.  Pre-pregnancy kidney function and subsequent adverse pregnancy outcomes.

Authors:  Emily W Harville; Janet Catov; C Elizabeth Lewis; Kirsten Bibbins-Domingo; Erica P Gunderson
Journal:  Pregnancy Hypertens       Date:  2019-02-01       Impact factor: 2.494

5.  Evidence of Augmented Intrarenal Angiotensinogen Associated With Glomerular Swelling in Gestational Hypertension and Preeclampsia: Clinical Implications.

Authors:  Hiten D Mistry; Lesia O Kurlak; David S Gardner; Ole Torffvit; Alastair Hansen; Fiona Broughton Pipkin; Helena Strevens
Journal:  J Am Heart Assoc       Date:  2019-06-25       Impact factor: 5.501

6.  A pilot study of alterations in oxidized angiotensinogen and antioxidants in pre-eclamptic pregnancy.

Authors:  Lina A Dahabiyeh; David Tooth; Lesia O Kurlak; Hiten D Mistry; Fiona Broughton Pipkin; David A Barrett
Journal:  Sci Rep       Date:  2020-02-06       Impact factor: 4.379

7.  Volume regulatory hormones and plasma volume in pregnant women with sickle cell disorder.

Authors:  Bosede B Afolabi; Olajumoke O Oladipo; Alani S Akanmu; Olalekan O Abudu; Olusoga A Sofola; Fiona Broughton Pipkin
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2016-09-27       Impact factor: 1.636

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.